Since arriving in Wuhan on October 26th, 65438, Academician Chen Wei, together with local advantageous enterprises, has been working against time to carry out the research on pharmacy, pharmacodynamics, pharmacology and toxicology of recombinant novel coronavirus vaccine, and has quickly completed the design of COVID-19 vaccine, the construction of recombinant virus species, the production and preparation under GMP conditions, the safety, effectiveness evaluation and quality review of third-party vaccines.
Extended data:
Research and development of vaccines abroad;
America 1
On February 19, 2020, Sanofi Pasteur, the global vaccine division of Sanofi, announced that it would cooperate with BARDA and use the advanced gene recombination technology platform to accelerate the research and development of novel coronavirus vaccine.
On March 2, 2020, the University of California, Riverside, issued a statement saying that the research team discovered the drug target protein in COVID-19 and cracked the 3D structure of the protein, which will help to develop drugs for treating COVID-19. The research team consists of researchers from the University of California, Riverside, the University of Chicago, the Argon National Laboratory of the US Department of Energy and Northwestern University.
2. Russia
On February 26th, 2020, Russian Deputy Prime Minister Gorikova told the media that Russian researchers had obtained novel coronavirus strain and developed five prototype vaccines against the virus. Russian "Vector" National Center for Virology and Biotechnology has developed five prototype vaccines for COVID-19, but they are still in the initial stage of vaccine development.
Baidu Encyclopedia-novel coronavirus Vaccine
Public trust. Recombinant COVID-19 vaccine allowed to start clinical trials.